FSD Pharma: Jumps on mid-stage trial of potential COVID-19 drug
05/10/2020 13:24
** U.S.-listed shares of Canadian pharma co HUGE.O up 8.4%
at $2.6 premarket
** Begins phase 2 clinical trial to evaluate FSD201 for
treatment of hospitalized COVID-19 patients urn:newsml:reuters.com:*:nBwbrfpgCa
** U.S. FDA authorized mid-stage trial; co expects to start
dosing patients in Oct
** "We are joining the global fight against the deadly
SARS-CoV-2 virus with a hope to demonstrate down-regulation of
the over-expressed immune response in COVID-19 patients leading
to better treatment outcome." - CEO
** Up to Friday's close, stock down ~54% YTD
(Reporting by Shivani Kumaresan in Bengaluru)
((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;))